For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants

Viruses. 2022-01; 
Tasnim Saifudin Zakir, Tao Meng, Lee Ching Pei Carmen, Justin Jang Hann Chu, Raymond Tzer Pin Lin, Mookkan Prabakaran
Products/Services Used Details Operation
Recombinant Proteins … Louis, MO, USA). The mice were boosted with the spike RBD (Z03483, GenScript, Piscataway, NJ, USA) 3 days before the fusion of splenocytes with SP2/0 cells … Get A Quote


The constant mutation of SARS-CoV-2 has led to the emergence of new variants, which call for urgent effective therapeutic interventions. The trimeric spike (S) protein of SARS-CoV-2 is highly immunogenic with the receptor-binding domain (RBD) that binds first to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and is therefore the target of many neutralizing antibodies. In this study, we characterized a broadly neutralizing monoclonal antibody (mAb) 9G8, which shows potent neutralization against the authentic SARS-CoV-2 wild-type (WT), Alpha (B.1.1.7), and Delta (1.617.2) viruses. Furthermore, mAb 9G8 also displayed a prominent neutralizing efficacy in the SARS-CoV-2 surrogate virus neutralization t... More


SARS-CoV-2 variants, cross-neutralizing antibody, escape mutant, neutralizing epitope, spike RBD